Gastrointestinal stromal tumors, commonly abbreviated as GISTs, arise from the interstitial cells of Cajal or their precursors in the wall of the digestive tract. The majority of cases are driven by activating mutations in the KIT or PDGFRA receptor tyrosine kinase genes, and targeted drugs such as imatinib have transformed treatment for many patients. Yet resistance to tyrosine kinase inhibitors develops with sobering regularity, and secondary mutations in the kinase domain frequently blunt the effectiveness of later-line agents such as sunitinib and regorafenib. For patients whose tumors progress through all available targeted therapies, options remain severely limited. This therapeutic ceiling has pushed researchers to look beyond the kinase signaling axis itself and to ask what downstream and parallel programs allow GIST cells to survive, adapt, and spread. The new study addresses precisely that question by focusing on how the tumor’s metabolic and epigenetic machinery conspires to lock cells into a malignant state.

At the center of the investigation is lactylation, an epigenetic mark first described in 2019 that attaches lactate-derived lactyl groups to lysine residues on histone proteins, the spools around which DNA is wound. The discovery of histone lactylation resolved a long-standing puzzle: elevated lactate, long dismissed as a mere waste product of glycolysis, appeared to actively stimulate gene expression, but the mechanism was unknown. It is now understood that when cells engage in high rates of glycolysis, whether because of oxygen deprivation or because of the Warburg effect that characterizes many cancers, pyruvate is converted to lactate in large quantities, and a fraction of that lactate enters the nucleus. There, enzymes can transfer the lactyl group onto histone lysines, creating histone lactylation marks that physically loosen the interaction between histones and DNA and recruit reader proteins that activate transcription. In essence, a cell’s metabolic state can be written directly into its chromatin, turning genes on or off in response to how the cell feeds itself. In cancers, this creates a self-reinforcing loop in which the metabolic frenzy of the tumor rewrites its own gene expression program to become more aggressive.

The research team identified fibronectin 1, or FN1, as a critical node in this loop in GIST. Fibronectin 1 is a high-molecular-weight glycoprotein normally secreted into the extracellular matrix, where it mediates cell adhesion, migration, and wound healing. In many solid tumors, including several sarcoma subtypes, FN1 is overexpressed and is associated with invasion, metastasis, and poor clinical outcomes. The new work elevates FN1 from a passive correlate of aggressive disease to an active driver: the authors demonstrate that fibronectin 1 mediated histone lactylation promotes the malignant progression of GIST. In practical terms, the tumor’s own extracellular and metabolic environment, rich in lactate, appears to induce lactylation marks on histones that switch on a transcriptional program favoring proliferation, invasion, and survival, with fibronectin 1 both participating in and amplifying this program.

What makes the study particularly novel is the regulatory layer sitting above this process. The researchers show that the FN1-lactylation axis in GIST is regulated by m6A modification of RNA. N6-methyladenosine is a reversible chemical mark deposited on adenosine bases within messenger RNAs by writer enzymes of the METTL family, principally the METTL3–METTL14 complex, and removed by eraser enzymes such as FTO and ALKBH5. The consequences of m6A deposition depend on which reader proteins recognize the mark: YTHDF family proteins and YTHDC proteins can accelerate mRNA decay, enhance translation, or alter RNA processing and export. Over the past decade, m6A has emerged as a master regulator of cancer-relevant transcripts, and dysregulation of its writers, erasers, and readers has been documented across a wide range of malignancies. In this study, m6A modification acts as the conductor of the orchestra, determining the abundance and behavior of the FN1 message and thereby calibrating the intensity of the lactylation-driven malignant program.

The mechanistic chain the authors propose can be summarized as follows. Altered m6A dynamics in GIST cells, involving shifts in the activity of methyltransferases and demethylases, change how fibronectin 1 messenger RNA is processed, degraded, or translated, leading to elevated FN1 expression or enhanced FN1 function. Fibronectin 1, in turn, is tied to increased glycolytic flux and lactate accumulation, which fuel histone lactylation. The resulting lactylated histones activate promoters and enhancers of genes that promote malignancy, creating a feed-forward circuit in which epigenetic activation of metabolic and pro-invasive genes sustains the very metabolic conditions that generate the lactyl marks in the first place. Disrupting any point in this circuit, the study suggests, could weaken the loop and slow tumor progression. The authors’ experimental framework, combining molecular profiling of GIST specimens with mechanistic assays in cellular models, supports each link in this chain, although translating the full loop into clinical interventions will require further validation.

From a translational standpoint, the study offers several potential points of attack. Drugs that inhibit lactate production or export, such as inhibitors of lactate dehydrogenase A or monocarboxylate transporters, are already in preclinical and early clinical development for other cancers and could be repurposed for GIST. Similarly, small-molecule inhibitors of the m6A writer METTL3 have entered early-phase clinical trials, and compounds that modulate reader proteins are advancing rapidly. The lactylation machinery itself is also becoming druggable, as researchers have identified enzymes, including members of the p300 family of histone acetyltransferases and, more recently, deacylating enzymes capable of removing lactyl marks, that could be targeted to strip lactylation from histones. A combination strategy that simultaneously dampens lactate generation and blocks the m6A-dependent upregulation of FN1 could, in principle, collapse the entire feed-forward circuit that the study describes.

The work also carries important implications for biomarker development. Because fibronectin 1 is a secreted, matrix-associated protein and because m6A-related enzymes and histone lactylation marks can be measured by immunohistochemistry and sequencing-based assays, the molecular signature defined in this study could potentially be developed into a stratification tool. Patients whose tumors display high FN1 expression, strong lactylation marks, and dysregulated m6A machinery might be identified as having an elevated risk of progression or resistance to standard tyrosine kinase inhibitors, allowing clinicians to escalate therapy earlier or to enroll such patients in trials of metabolism- and epigenetics-targeted agents. Conversely, patients lacking this signature might be spared more aggressive interventions. Such stratification remains speculative until the findings are validated in larger, prospective cohorts, but the study provides the biological rationale needed to pursue it.

The broader scientific significance of the paper lies in its demonstration that three independently discovered layers of cellular regulation, RNA modification, protein lactylation, and chromatin state, do not operate in isolation but can be wired together into a coherent oncogenic circuit. Histone lactylation was originally characterized in macrophages responding to bacterial infection, where it linked inflammatory metabolism to gene activation, and it has since been implicated in tumors ranging from renal cell carcinoma to gastric and liver cancers. Studies linking m6A to lactate metabolism have begun to appear in other cancer types as well. By connecting these threads in GIST, a tumor type in which metabolic reprogramming had received comparatively little attention, the new research expands the conceptual map of how sarcomas progress and suggests that metabolism-epigenetics crosstalk may be a general feature of mesenchymal malignancies rather than a peculiarity of epithelial cancers.

Looking ahead, the authors and the field face clear next steps. The precise enzymes responsible for writing and erasing histone lactylation in GIST cells need to be definitively mapped, and the specific genomic loci whose activation depends on lactylated histones should be catalogued genome-wide to identify the full set of malignant effector genes downstream of FN1. Animal models of GIST, particularly patient-derived xenografts carrying KIT mutations, will be essential to test whether pharmacological disruption of the m6A–FN1–lactylation axis delays progression or sensitizes tumors to existing kinase inhibitors. Clinical validation in tissue banks from imatinib-treated patients could determine whether the signature predicts drug resistance. If those efforts succeed, a disease that has been treated almost exclusively through the lens of kinase signaling for the past two decades may gain an entirely new therapeutic dimension, one built on the chemistry of lactate, chromatin, and RNA.

Cancer remains a formidable global health challenge, with molecular complexity and adaptability often undermining therapeutic efficacy. Traditional strategies targeting kinases or DNA replication have delivered significant benefits but are frequently thwarted by acquired resistance. PF-3758309, initially characterized as a potent inhibitor of PAK4 (p21-activated kinase 4), has demonstrated robust anti-cancer activity across various tumor models. However, its precise mechanisms had remained elusive, preventing the refinement and broader application of this compound in clinical oncology. The new research provides a pivotal mechanistic understanding that could accelerate the development of PF-3758309-based therapies.

The research team applied a comprehensive multi-omics workflow integrating transcriptomics, proteomics, and ubiquitin-proteomics to decode the cellular response landscape evoked by PF-3758309 treatment. This integrative approach enabled the delineation of complex molecular interactions and regulatory networks influenced by the drug. Strikingly, the data revealed substantial downregulation of RNA polymerase II subunits at the protein level, accompanied by enhanced ubiquitination signaling, a hallmark of targeted protein degradation pathways. These findings implicated the ubiquitin-proteasome system in orchestrating the removal of RNA polymerase II under pharmacological pressure.

RNA polymerase II is essential for the transcription of most protein-coding genes, serving as the molecular machine that reads DNA templates and synthesizes messenger RNA. Its role is absolutely critical for maintaining cellular homeostasis and proliferation. The discovery that PF-3758309 induces proteasomal degradation of RNA polymerase II marks a paradigm shift, suggesting that disruption of transcriptional machinery can be a viable anti-cancer strategy. This mechanism contrasts starkly with conventional inhibitors, which typically impede enzyme activity without promoting degradation.

Further mechanistic investigations revealed that PF-3758309 treatment enhances the activity of specific E3 ubiquitin ligases that tag RNA polymerase II with ubiquitin moieties. This post-translational modification earmarks the enzyme for proteasomal degradation. The study identified candidate E3 ligases implicated in this process, highlighting a cascade wherein PF-3758309 indirectly engages the ubiquitin machinery to target transcriptional apparatus for destruction. This intricate crosstalk underscores the sophistication of the drug’s mode of action beyond straightforward enzyme inhibition.

Functional assays underscored the biological consequences of RNA polymerase II degradation in cancer cells. Treated tumor cells exhibited profound transcriptional repression, leading to cell cycle arrest and apoptotic cell death. Importantly, the selectivity of PF-3758309 towards malignant cells versus normal cells was confirmed, suggesting a therapeutic window that could minimize off-target toxicity. This selectivity likely stems from the heightened dependency of tumor cells on robust transcriptional programs to sustain their uncontrolled growth.

The researchers extended their findings across multiple cancer types, including breast, lung, and colon carcinomas, demonstrating consistent RNA polymerase II degradation upon PF-3758309 exposure. This broad-spectrum effect indicates that the molecular vulnerability targeted by the compound is conserved across diverse malignant contexts. Such versatility makes PF-3758309 a promising candidate for further preclinical and clinical evaluation in heterogeneous tumor settings.

This study also employed in vivo murine xenograft models to validate the anti-tumor efficacy of PF-3758309 in a physiological context. Tumor-bearing mice receiving the compound showed significant tumor volume reduction, correlating with decreased RNA polymerase II expression in tumor tissues. The in vivo results corroborate the in vitro mechanistic insights, reinforcing the potential translational impact of RNA polymerase II degradation-driven therapeutic strategies.

Importantly, the identification of RNA polymerase II as a degradation target raises compelling questions about the cellular stress responses activated by transcriptional collapse. The researchers observed induction of DNA damage response pathways and signaling alterations linked to the unfolded protein response, illustrating a complex network of adaptive and lethal processes triggered by PF-3758309. Further exploration of these secondary effects could inform combination treatment regimens that amplify anti-tumor efficacy.

Advancing from discovery to therapeutic application will require overcoming potential challenges related to specificity and the development of resistance mechanisms. As RNA polymerase II is a fundamental cellular component, prolonged inhibition or degradation could risk toxicity in highly proliferative normal tissues. The partial selectivity observed in cancer cells offers optimism, but the therapeutic window must be rigorously defined through dose optimization and biomarker development to identify responsive patient populations.

The study’s multi-omics approach serves as a model for future drug mechanism investigations, illustrating how integrated analyses can unravel complex pharmacodynamics. By converging data across molecular layers, the researchers provided a comprehensive overview of how PF-3758309 reprograms cancer cell transcriptional machinery, challenging conventional drug characterization paradigms. This methodological advance will likely propel the discovery of analogous pathways in other compounds with elusive targets.

Looking ahead, the therapeutic exploitation of RNA polymerase II degradation invites exciting prospects beyond oncology. Since transcriptional deregulation underpins diverse pathological conditions, the principles uncovered here may inform strategies against viral infections or inflammatory diseases where aberrant gene expression is pathogenic. Moreover, harnessing the ubiquitin-proteasome system to degrade nuclear enzymes represents a fertile ground for drug development expanding the repertoire of ‘degrader’ molecules beyond current technologies like PROTACs.

The reported findings have already sparked significant interest within the scientific and pharmaceutical communities. By elucidating a novel mechanism of action for PF-3758309, this work invigorates efforts to design next-generation transcription-targeting agents that combine potency with specificity. The path from bench to bedside could be accelerated by leveraging structural biology insights and chemical optimization to enhance drug-like properties and minimize adverse effects.

In summary, the revelation that PF-3758309 induces the degradation of RNA polymerase II presents a transformative concept in cancer therapy. This mechanism disrupts the very foundation of cancer cell survival—the transcriptional machinery—thereby offering a potent strategy to impede tumor growth. The study’s comprehensive multi-omics analysis not only deepens our understanding of PF-3758309’s anti-tumor activity but also highlights the broader therapeutic potential of regulating RNA polymerase II stability. As research continues, this discovery may herald a new class of targeted treatments with profound clinical impact.

Subject of Research: Molecular mechanisms underlying the anti-tumor activity of PF-3758309, focusing on transcriptional machinery disruption.

Article Title: Multi-omics analysis reveals RNA polymerase II degradation as a novel mechanism of PF-3758309’s anti-tumor activity.

Article References:
Jia, X., Zhang, J., Pan, L. et al. Multi-omics analysis reveals RNA polymerase II degradation as a novel mechanism of PF-3758309’s anti-tumor activity. Cell Death Discov. 11, 404 (2025). https://doi.org/10.1038/s41420-025-02677-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02677-5